Polaris Oncology Survivor Transition (POST) System

计划入组 200 人 · 首次发布于 2015 年 12 月 22 日

Prospective, Post Market Surveillance Q3-registry (POLARIS)

计划入组 250 人 · 首次发布于 2014 年 12 月 4 日

STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study

计划入组 28 人 · 首次发布于 2025 年 12 月 8 日

Polaris

Polaris program (undisclosed inflammatory indication)

Ethylaminobenzylmethylcarbonyl Group

C₁₇H₂₄N₂O₃

Procaps Group

Luxembourg

ROCHET GROUP

France

SVR GROUP

France

ADI-PEG20 Quadruples Three-Year Survival in Phase 3 Mesothelioma Trial

AriBio's AR1001 Phase 3 Trial for Early Alzheimer's Enrolls First Patients

AriBio and Fujirebio Complete Major Biomarker Sample Collection for Alzheimer's Research in Phase 3 POLARIS-AD Trial